AMYLYX PHARMACEUTICALS INC
AMLXNASDAQπ #1494 by market capUS Equity
$26.05β
Last available close Β· quote unavailableTrack AMLX
Get earnings, price moves & breaking news on Telegram
24hβ
7dβΌ 14.0%
14dβΌ 11.8%
30dβΌ 4.2%
ytdβ² 115.5%
1yβ² 77.3%
π¦Market Cap
$3.35B
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
82.8%
High
π΅FCF Margin
β
βοΈP/S Ratio
17.0x
Expensive
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $10.83 β $41.14
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 125.5M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 17.0x
- EPS (TTM)
- $-1.43
- Dividend Yield
- β
- Dilution (1yr)
- +37.9%
AMYLYX PHARMACEUTICALS INC
AMLXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0βΌ β100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.8%βΌ β44.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$153MβΌ β51.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$123MβΌ β26.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
94.6Mβ² +37.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$221Mβ² +$145M YoY
About AMYLYX PHARMACEUTICALS INC
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
18 analysts
Strong Buy9
Buy7
Hold2
Sell0
Strong Sell0
Ratings as of Nov 2026
Latest News & Updates
News unavailable.